Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-05-30
1999-10-12
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142342, 514263, 544 61, 544118, 544229, 544272, C07D47304, C07D47306, A61K 3152, C07F 710
Patent
active
059655550
ABSTRACT:
Compounds of the formula I, ##STR1## in which one of the radicals R.sup.1 and R.sup.3 is an alkynol residue of the formula Ia or Ib ##STR2## are suitable for producing pharmaceuticals having a neuroprotective effect.
REFERENCES:
patent: 4007197 (1977-02-01), Christensen et al.
Chalmers, TiPS 17, 166 Apr. 1996.
Cai, Helv. Chim. Acta 78, 732, 1995.
Ohnuma, Te. Letters 27, 219, 1986.
Mulzer, Ann. Chem 1992, 1131, 1992.
Abel, Angnew. CHem 106, 2522, 1994.
Peruche, Pharmazeutische Zeitung 1994, 139/31, 2482-3.
Lyrer, Schweiz. Med. Wochenschr. 1994, 124/45, 2005-12.
Sandercock et al, Lancet 1992, 339/8792, 537-9.
Leys et al, Rev. Med. Interne 1994,, 15/5, 350-6. (Abstract only).
Fisher, Stroke 1990, 21/8 Suppl. 1, I-130-I-131.
Puruche et al, Prog. Neuropsychopharmacol. Biol. Psychiatry 1993, 17/1, 20-70.
Ferrer et al, Clin. Neuropharmacol. 1990, 13 Suppl. 3, S9-S25.
Sila et al, Drugs 1988, 35/4, 468-76.
Frampton et al, Drugs & Aging 1995, 7/6, 480-503.
Uldry et al, Schweiz., Rundsch. Med. Prax. 1989, 78/23, 663-6.
Parkinson et al, Gen. Pharmac. 1994, 25/6; 1053-8.
Williams, Drug Dev. Res. 1993, 28/3, 438-44.
Huber et al, J. Cereb. Blood Flow Metab. 1993, 13/3, 526-30. (Abstract only).
Corriu et al, Tetrahedron 1992, 48/30, 6231-44.
Lundkvist et al, J. Med. Chem. 1990, 33, 3182-9.
Imamoto et al, Tetrahedron Letters 1984, 25/38, 4233-6.
Lyrer, Schweiz. Med. Wochenschr. 1994, 124,45, 2005-12.
Rudolphi et al, J. Cereb. Blood Flow Metab. 1987, 7/1, 74-81.
Tamura et al, J. Cereb. Blood Flow Metab. 1981, 1, 53-60.
Bederson et al, Stroke 1986, 17, 472-76.
Park et al, Neurosci. Lett. 1992, 147, 41-44.
Park et al, Neurosci. Lett. 1994, 178, 235-238.
Backhauss et al, J. Pharm. Meth. 1992, 27, 27-32.
Zue et al, Brain Res. 1992, 587, 66-72.
Weygang/Hilgetag: Organisch Chemische Experimentierkunst 4. Auf. (1970) 990-993.
Pschyrembel Klinisches Woterbuch 255. Auf. Walter de Gruter (1986) 105 +1840.
ROMPP Chemie Lexikon 9. Auf., Band 4 (1991) 2632 +2954.
Chemical Abstract 70:37787h (1969), Johannes Reisch, "Synthesis and effect of drugs. VI. Preparation of some N-alkynyl xanthine derivatives". (Inst. Pharm. Chem. Westf. Wilheims-Univ., Muenster/Westf., Arzneim-Forsch, 1968, 18(11), 1485-6.
Chemical Abstract 88:68922Z (1978), Johannes Reisch, et al., "The Synthesis and activity of potential drugs, part 14, Metabolism 7-(3-butynyl)theophylline in rats.", (Inst. Pharm. Chem., Westfael. Wilhelms-Univ., Muenster, Arch Pharm. (Weinheim) 1977, 310(11), 888-93.
Defossa Elisabeth
Gebert Ulrich
Grome John J.
Heinelt Uwe
Rudolphi Karl
Berch Mark L.
Hoechst Aktiengesellschaft
LandOfFree
Xanthine compounds having terminally animated alkynol side chain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Xanthine compounds having terminally animated alkynol side chain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Xanthine compounds having terminally animated alkynol side chain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-652657